Full Press Release Details
CHF Solutions, Inc. Announces 27% Revenue Growth for its Second Quarter and Provides Company Update
Eden Prairie, MN: August 7, 2018: CHF Solutions, Inc. (NASDAQ: CHFS) announced today its second quarter results for the period ended June 30, 2018. Highlights include:
"We have continued to incrementally execute on our expansion strategy, including continued upward trends in our revenue," said John Erb, Chairman and CEO. "We continue to be optimistic about our future growth and look forward to reporting further developments."
The Company will host a conference call and webcast at 9:00 AM ET today to discuss its financial results and provide an update on the Company's performance.
To access the live webcast, please visit the Investors page of the CHF Solutions website at www.chf-solutions.com. Alternatively, you may access the live conference call by dialing (877) 303-9826 (U.S.) or (224) 357-2194 (international) and using conference ID 8576075. An audio archive of the webcast and a transcript of the call will be available following the call on the Investor page at www.chf-solutions.com.
CHF Solutions, Inc. (NASDAQ:CHFS) is a medical device company focused on commercializing the Aquadex FlexFlow system for Aquapheresis therapy. The Aquadex FlexFlow system, is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a healthcare provider, under physician prescription, both of whom having received training in extracorporeal therapies. The company's objective is to improve the quality of life for patients with heart failure and related conditions. CHF Solutions is a Delaware corporation headquartered in Minneapolis with wholly owned subsidiaries in Australia and Ireland. The company has been listed on the NASDAQ Capital Market since February 2012.
Forward-Looking Statements
Certain statements in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, the statement regarding the benefits from using the Aquadex FlexFlow, trends in our revenue, our expansion plan and our future growth and developments. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our ability to execute on our business strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. CHF Solutions does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
CHF SOLUTIONS, INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Operations and Comprehensive Loss
(Unaudited and in thousands, except per share amounts)
| Three months ended June 30, | Six months ended June 30, | |||||||||||||||
| 2018 | 2017 | 2018 | 2017 | |||||||||||||
| Net sales | $ | 1,099 | $ | 864 | $ | 2,136 | $ | 1,765 | ||||||||
| Costs and expenses: | ||||||||||||||||
| Cost of goods sold | 870 | 616 | 1,771 | 1,130 | ||||||||||||
| Selling, general and administrative | 3,765 | 2,420 | 7,776 | 4,807 | ||||||||||||
| Research and development | 643 | 327 | 1,122 | 635 | ||||||||||||
| Total costs and expenses | 5,278 | 3,363 | 10,669 | 6,572 | ||||||||||||
| Loss from operations | (4,179 | ) | (2,499 | ) | (8,533 | ) | (4,807 | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Other income, net | - | 5 | - | 11 | ||||||||||||
| Warrant valuation expense | - | - | - | (67 | ) | |||||||||||
| Change in fair value of warrant liability | - | 37 | - | 1,466 | ||||||||||||
| Total other income, net | - | 42 | - | 1,410 | ||||||||||||
| Loss before income taxes | (4,179 | ) | (2,457 | ) | (8,533 | ) | (3,397 | ) | ||||||||
| Income tax benefit (expense), net | (2 | ) | (1 | ) | (2 | ) | (1 | ) | ||||||||
| Net loss | $ | (4,181 | ) | $ | (2,458 | ) | $ | (8,535 | ) | $ | (3,398 | ) | ||||
| Basic and diluted loss per share | $ | (0.93 | ) | $ | (9.38 | ) | $ | (2.00 | ) | $ | (27.77 | ) | ||||
| Weighted average shares outstanding - basic and diluted | 4,494 | 371 | 4,263 | 225 | ||||||||||||
| Other comprehensive loss: | ||||||||||||||||
| Foreign currency translation adjustments | $ | (2 | ) | $ | (5 | ) | $ | (1 | ) | $ | (6 | ) | ||||
| Total comprehensive loss | $ | (4,183 | ) | $ | (2,463 | ) | $ | (8,536 | ) | $ | (3,404 | ) |
CHF SOLUTIONS, INC. AND SUBSIDIARIES
Condensed Consolidated Balance Sheets
(in thousands, except share and per share amounts)
| June 30, 2018 (unaudited) | December 31, 2017 | |||||||
| ASSETS | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 6,995 | $ | 15,595 | ||||
| Accounts receivable | 652 | 545 | ||||||
| Inventory | 2,315 | 1,588 | ||||||
| Other current assets | 205 | 136 | ||||||
| Total current assets | 10,167 | 17,864 | ||||||
| Property, plant and equipment, net | 576 | 570 | ||||||
| Other assets | 195 | 21 | ||||||
| TOTAL ASSETS | $ | 10,938 | $ | 18,455 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| Current liabilities | ||||||||
| Accounts payable and accrued expenses | $ | 838 | $ | 862 | ||||
| Accrued compensation | 979 | 1,021 | ||||||
| Other current liabilities | 186 | 208 | ||||||
| Total current liabilities | 2,003 | 2,091 | ||||||
| Other liabilities | 126 | 126 | ||||||
| Total liabilities | 2,129 | 2,217 | ||||||
| Commitments and contingencies | - | - | ||||||
| Stockholders' equity | ||||||||
| Series A junior participating preferred stock as of June 30, 2018 and December 31, 2017, par value $0.0001 per share; authorized 30,000 shares, none outstanding | - | - | ||||||
| Series F convertible preferred stock as of June 30, 2018 and December 31, 2017, par value $0.0001 per share; authorized 610 and 3,780 shares, respectively, issued and outstanding 610 and 3,780, respectively | - | - | ||||||
| Preferred stock as of June 30, 2018 and December 31, 2017, par value $0.0001 per share; authorized 39,969,390 and 39,966,220 shares, none outstanding | - | - | ||||||
| Common stock as of June 30, 2018 and December 31, 2017, par value $0.0001 per share; authorized 100,000,000 shares, issued and outstanding 4,505,953 and 3,798,929, respectively | - | |||||||
| Additional paid in capital | 198,474 | 197,367 | ||||||
| Accumulated other comprehensive income: | ||||||||
| Foreign currency translation adjustment | 1,226 | 1,227 | ||||||
| Accumulated deficit | (190,891 | ) | (182,356 | ) | ||||
| Total stockholders' equity | 8,809 | 16,238 | ||||||
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ | 10,938 | $ | 18,455 |
CHF SOLUTIONS, INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Cash Flows
(Unaudited, in thousands)
| Six months ended June 30, | ||||||||
| 2018 | 2017 | |||||||
| Operating Activities: | ||||||||
| Net loss | $ | (8,535 | ) | $ | (3,398 | ) | ||
| Adjustments to reconcile net loss to cash flows used in operating activities: | ||||||||
| Depreciation and amortization expense | 115 | 436 | ||||||
| Stock-based compensation expense, net | 1,107 | 281 | ||||||
| Change in fair value of warrant liability | - | (1,466 | ) | |||||
| Warrant valuation expense | - | 67 | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | (107 | ) | (336 | ) | ||||
| Inventory | (727 | ) | (187 | ) | ||||
| Other current assets | (48 | ) | 8 | |||||
| Accounts payable and accrued expenses | (283 | ) | (1,103 | ) | ||||
| Net cash used in operations | (8,478 | ) | (5,698 | ) | ||||
| Investing Activities: | ||||||||
| Purchases of property and equipment | (121 | ) | (20 | ) | ||||
| Net cash used in investing activities | (121 | ) | (20 | ) | ||||
| Financing Activities: | ||||||||
| Net proceeds from public stock offering | - | 8,002 | ||||||
| Net proceeds from exercise of warrants | - | 1,768 | ||||||
| Net proceeds from the sale of preferred stock and warrants | - | 184 | ||||||
| Net cash (used in) provided by financing activities | - | 9,954 | ||||||
| Effect of exchange rate changes on cash | (1 | ) | (1 | ) | ||||
| Net (decrease) increase in cash and cash equivalents | (8,600 | ) | 4,235 | |||||
| Cash and cash equivalents - beginning of period | 15,595 | 1,323 | ||||||
| Cash and cash equivalents - end of period | $ | 6,995 | $ | 5,558 | ||||
| Supplement schedule of non-cash activities | ||||||||
| Warrants issued as inducement to warrant exercise | $ | - | $ | 509 | ||||
| Conversion of temporary equity to permanent equity | $ | - | $ | 485 | ||||
| Financing fees included in long-term assets and accounts payable | $ | 195 | $ | - |
Claudia Napal Drayton
Chief Financial Officer